ES2051152B1 - Procedimiento de sistesis de peptidos con capacidad de detectar anticuerpos anti-virus de la hepatitis c (vhc) en suero de individuos afectados. - Google Patents

Procedimiento de sistesis de peptidos con capacidad de detectar anticuerpos anti-virus de la hepatitis c (vhc) en suero de individuos afectados.

Info

Publication number
ES2051152B1
ES2051152B1 ES09101525A ES9101525A ES2051152B1 ES 2051152 B1 ES2051152 B1 ES 2051152B1 ES 09101525 A ES09101525 A ES 09101525A ES 9101525 A ES9101525 A ES 9101525A ES 2051152 B1 ES2051152 B1 ES 2051152B1
Authority
ES
Spain
Prior art keywords
rsi2
rsi1
amino acids
peptides
aasi15
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES09101525A
Other languages
English (en)
Other versions
ES2051152A1 (es
Inventor
Lasarte Carmen Berasain
Marquez Marta Garcia-Granero
Jose Ignacio Riezu-Boj
Valtuena Jesus Prieto
Cuesta Francisco Borras
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Instituto Cientifico y Tecnologico de Navarra SA
Original Assignee
Instituto Cientifico y Tecnologico de Navarra SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instituto Cientifico y Tecnologico de Navarra SA filed Critical Instituto Cientifico y Tecnologico de Navarra SA
Priority to ES9301361A priority Critical patent/ES2069476B1/es
Publication of ES2051152A1 publication Critical patent/ES2051152A1/es
Application granted granted Critical
Publication of ES2051152B1 publication Critical patent/ES2051152B1/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

PROCEDIMIENTO DE SINTESIS DE PEPTIDOS CON CAPACIDAD DE DETECTAR ANTICUERPOSANTI-VIRUS DE LA HEPATITIS C (VHC) EN SUERO DE INDIVIDUOS INFECTADOS, TENIENDO DICHOS PEPTIDOS LA FORMULA GENERAL SIGUIENTE: RSI1-SC-AASI1-SC-AASI2-SC-AASI3-SC-AASI4-SC-AASI5-SC-AASI6-SC-AASI7-SC-AASI8-SC-AASI9-SC-AASI10-SC-AASI11-SC-AASI12-SC-AASI13-SC-AASI14-SC-AASI15-SC- RSI2-SC EN LA QUE RSI1-SC REPRESENTA H, RSI2-SC REPRESENTA OH, O BIEN RSI1-SC Y RSI2-SC REPRESENTAN CADENAS POLIPEPTIDICAS IGUALES O DIFERENTES QUE CONTIENEN ENTRE DOS O DIEZ AMINOACIDOS DE TAL FORMA QUE CUANDO RSI1-SC = H Y RSI2-SC = OH ENTONCES LA FORMULAREPRESENTA UN PENTADECAPEPTIDO EN QUE LOS AMINOACIDOS N-TERMINAL Y C-TERMINAL SON RESPECTIVAMENTE AASI1-SC Y AASI15-SC; AASI4-SC REPRESENTA SER O ARG; AASI5-SC REPRESENTA ARG, PRO O LYS; AASI6-SC REPRESENTA GLY, GLN O THR; AASI7-SC REPRESENTA ASN, ASP O LYS; AASI10-SC REPRESENTA SER, PHE O THR; AASI11-SC REPRESENTA PRO O ASN; AASI12-SC REPRESENTA THR, GLY O ARG; Y AASI1-SC, AASI2-SC, AASI3-SC, AASI8-SC, AASI13-SC, AASI14-SC, Y AASI15-SC REPRESENTA CADA UNO A ALGUNO DE LOS 20 POSIBLES AMINOACIDOS NATURALES, CARACTERIZADO POR LAS OPERACIONES SIGUIENTES: (A) FUNCIONALIZACION DE LA RESINA, (B) UNION DEL PRIMER AMINOACIDO A LA RESINA FUNCIONALIZADA, (C) ENSAMBLAMIENTO DE LOS RESTANTES AMINOACIDOS, (D) ESCISION DEL PEPTIDO DE LA RESINA, Y (E) PURIFICACION DEL PEPTIDO.
ES09101525A 1991-03-20 1991-06-28 Procedimiento de sistesis de peptidos con capacidad de detectar anticuerpos anti-virus de la hepatitis c (vhc) en suero de individuos afectados. Expired - Lifetime ES2051152B1 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES9301361A ES2069476B1 (es) 1991-06-28 1993-06-18 Procedimiento de sintesis de peptidos con capacidad de detectar anticuerpos ant-virus de la hepatitis c (vhc) en suero de individuos afectados.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919105871A GB9105871D0 (en) 1991-03-20 1991-03-20 Synthetic peptides
PCT/ES1993/000051 WO1995000545A1 (es) 1991-03-20 1993-06-18 Peptidos sinteticos para la deteccion de anticuerpos contra el virus de la hepatitis c en el suero de personas infectadas

Publications (2)

Publication Number Publication Date
ES2051152A1 ES2051152A1 (es) 1994-06-01
ES2051152B1 true ES2051152B1 (es) 1994-12-16

Family

ID=10691867

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09101525A Expired - Lifetime ES2051152B1 (es) 1991-03-20 1991-06-28 Procedimiento de sistesis de peptidos con capacidad de detectar anticuerpos anti-virus de la hepatitis c (vhc) en suero de individuos afectados.

Country Status (4)

Country Link
AU (1) AU4327793A (es)
ES (1) ES2051152B1 (es)
GB (1) GB9105871D0 (es)
WO (1) WO1995000545A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670310A (en) * 1994-07-29 1997-09-23 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for differential diagnosis of acute and chronic hepatitis c virus infection

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE206717T1 (de) * 1990-11-03 2001-10-15 Dade Behring Marburg Gmbh Hcv-spezifische peptide, mittel dazu und ihre verwendung
GB9028097D0 (en) * 1990-12-27 1991-02-13 Inst Technologico Y Cientifico New synthetic peptides active as immunomodulators
WO1992012992A2 (en) * 1991-01-14 1992-08-06 James N. Gamble Institute Of Medical Research Basic structural immunogenic polypeptides having epitopes for hcv, antibodies, polynucleotide sequences, vaccines and methods
US5574132A (en) * 1991-04-05 1996-11-12 Biochem Immunosystems Inc. Peptides and mixtures thereof for detecting antibodies to hepatitis C virus (HCV)
AU2683792A (en) * 1991-09-16 1993-04-27 Genelabs Technologies, Inc. Peptide based hepatitis c virus immunoassays

Also Published As

Publication number Publication date
GB9105871D0 (en) 1991-05-08
ES2051152A1 (es) 1994-06-01
AU4327793A (en) 1995-01-17
WO1995000545A1 (es) 1995-01-05

Similar Documents

Publication Publication Date Title
Blombäck et al. Primary Structure of Human Fibrinogen and Fibrin: II. STRUCTURAL STUDIES ON NH2-TERMINAL PART OF γ CHAIN
NO950668D0 (no) Peptider avledet fra et retrovirus fra HIV-gruppen og anvendelser derav
MX9606536A (es) Proteinas n-terminalmente extendidas expresadas en levaduras.
ES2112255T3 (es) Complejos proteicos que tienen actividad del factor viii:c y su produccion.
NO972930L (no) Fibronectin-adhesjonsinhibitorer
KR850003417A (ko) 폴리펩티드의 제조방법
ES2063350T3 (es) Nuevas proteinas con efecto inhibidor del tnf y su produccion.
Lin et al. The coat protein of the RNA bacteriophage MS2
KR850002283A (ko) 동종 면역 인터페론 단편의 제조방법
KR900017607A (ko) 프로테이나아제 억제제, 이것의 제조방법 및 이들을 함유한 의약품
Han et al. The covalent structure of beef heart myoglobin
KR880009125A (ko) 재조합 숙주에 의해 제조되는 췌장분비 트립신 억제제 및 그의 변이체, 그의 방법, 표현벡터 및 재조합 숙주 및 그의 제약상 용도
ES2052791T3 (es) Nuevos peptidos señal capaces de funcionar en levaduras, y expresion secretora de proteinas heterologas que utilizan los mismos.
BR9306272A (pt) Peptídeo e composiçao farmacêutica
DK0511188T3 (da) Hidtil ukendte bindingspeptider
FI961044A0 (fi) Kininogeeni-inhibiittorit
DE69827262D1 (de) Penaeidine: antimikrobielle peptide aus krebstieren
Adlersberg et al. Repetitive hinge region sequences in human IgG3: isolation of an 11,000-dalton fragment.
Gagnon et al. Primary structure of the A chain of human complement-classical-pathway enzyme C1r. N-terminal sequences and alignment of autolytic fragments and CNBr-cleavage peptides
Timpl et al. Cyanogen bromide cleavage of bovine fibrinogen. Identification of a dimeric N-terminal peptide and two other disulfide containing fragments
ES2051152B1 (es) Procedimiento de sistesis de peptidos con capacidad de detectar anticuerpos anti-virus de la hepatitis c (vhc) en suero de individuos afectados.
KR860006484A (ko) 단백질 또는 당단백질의 제조방법
KR930000684A (ko) 클로닝된 글루탐산 탈탄산효소
KATSOYANNIS Synthetic insulins
Meloun et al. Amino acid sequence of 37 residues at the carboxyl—terminal end of human plasma albumin